Alimta
Drug
Lilly USA, LLC
Total Payments
$195,430
Transactions
5
Doctors
0
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $195,430 | 5 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $195,430 | 5 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE II STUDY OF PEMETREXED LLY231514 FOR ONCOLOGY | Lilly USA, LLC | $109,678 | 0 |
| RANDOMIZED OPEN LABEL PHASE 3 STUDY OF PEMETREXED PLUS CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY MAINTENANCE PEMETREXED AND BEVACIZUMAB VERSUS PACLITAXEL PLUS CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB IN PATIENTS WITH STAGE IIIB OR IV | Eli Lilly and Company | $70,006 | 0 |
| A STUDY OF PEMETREXED PLUS CARBOPLATIN FOLLOWED BY MAINTENANCE PEMETREXED VS PACLITAXEL PLUS CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB IN PATIENTS WITH ADVANCED NCSLC OF NONSQUAMOUS HISTOLOGY | Lilly USA, LLC | $15,745 | 0 |
Top Doctors Receiving Payments for Alimta
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Nashville, TN | $195,430 | 5 |
Ad
Manufacturing Companies
- Lilly USA, LLC $125,424
- Eli Lilly and Company $70,006
Product Information
- Type Drug
- Total Payments $195,430
- Total Doctors 0
- Transactions 5
About Alimta
Alimta is a drug associated with $195,430 in payments to 0 healthcare providers, recorded across 5 transactions in the CMS Open Payments database. The primary manufacturer is Lilly USA, LLC.
Payment data is available from 2017 to 2017. In 2017, $195,430 was paid across 5 transactions to 0 doctors.
The most common payment nature for Alimta is "Unspecified" ($195,430, 100.0% of total).
Alimta is associated with 3 research studies, including "A PHASE II STUDY OF PEMETREXED LLY231514 FOR ONCOLOGY" ($109,678).